Legend Biotech Corporation, the majority-owned cell therapy arm of Hong Kong-based life science firm Genscript Biotech, has entered into an agreement to raise about $150.5 million, according to a regulatory filing with the Hong Kong Stock Exchange (HKEX) on March 31.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in